Spots Global Cancer Trial Database for t790m mutation
Every month we try and update this database with for t790m mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | NCT02759835 | Lung Adenocarci... Lung Neoplasms | osimertinib Local Ablative ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC | NCT05862194 | Non-small Cell ... | Lazertinib Platinum-based ... | 18 Years - | Yuhan Corporation | |
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | NCT02274337 | Non-Small Cell ... | AC0010 | 18 Years - 70 Years | Sun Yat-sen University | |
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | NCT02759835 | Lung Adenocarci... Lung Neoplasms | osimertinib Local Ablative ... | 18 Years - | National Institutes of Health Clinical Center (CC) |